Trial Profile
A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Smokers to Investigate the Effect of Inhaled Dosing With MMI-0100 on Airway Inflammation as Assessed in Induced Sputum After Challenge With Inhaled Lipopolysaccharide (LPS)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs MMI 0100 (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Sponsors Moerae Matrix
- 23 May 2018 Results assessing the safety, tolerability and PK profile of IH MMI-0100 in three Phase I trials (n=75) presented at the 114th International Conference of the American Thoracic Society
- 23 May 2018 Results presented at the 114th International Conference of the American Thoracic Society
- 30 Jul 2015 New trial record